Operational sustainability is threatened by a persistent cash burn, evidenced by a $4.5 million negative free cash flow in 2025Q1 and a reliance on stock-based compensation, which reached $1.4 million in 2024Q3, to preserve liquidity.
| Cash from Operations | -22.84M | -26.13M | -40.45M | -59.6M | -33.4M | -2.28M | -35K |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | 123.47% | 35.41% | 32.13% | -78.44% | -1365.64% | -6411.65% | - |
| Net Income | -22.64M | -30.07M | -40.16M | -65.37M | -39.31M | -10.38M | -54K |
| Depreciation & Amortization | 826K | 1.09M | 915K | 939K | 340K | 20K | 0 |
| Stock-Based Compensation | 3.38M | 3.47M | 3.56M | 10.06M | 23.31M | 4.38M | 1.2K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -3.91M | -438K | -583K | -4.21M | -23.36M | 4.66M | 7K |
| Working Capital Changes | -491K | -178K | -4.19M | -1.02M | 5.61M | -959K | 10.8K |
| Change in Receivables | 1.04M | 0 | 328K | 200K | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | -200K | 0 | 0 | 0 |
| Change in Payables | -45K | -468K | -1.57M | 1.05M | 1.53M | 456K | 35K |
| Cash from Investing | 212K | 212K | 41.5M | -40.58M | -5.26M | -65.64M | -65.64M |
| Capital Expenditures | 0 | 0 | 0 | 0 | -5.26M | 0 | 0 |
| CapEx % of Revenue | 0% | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | -65.64M | -65.64M |
| Cash from Financing | 21.84M | 17.99M | 114K | 280K | 88.45M | 64.07M | 66.46M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 21.73M | 17.87M | 0 | 0 | 47.43M | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 113K | 118K | 114K | 280K | 41.02M | 64.07M | 66.46M |
| Net Change in Cash | -673K | -7.79M | 1.12M | -99.83M | 49.77M | 61.79M | 790.04K |
| Free Cash Flow | -22.84M | -26.13M | -40.45M | -59.6M | -38.66M | -2.28M | -35K |
| FCF Margin % | -2138.76% | - | - | - | - | - | - |
| FCF Growth % | 34.92% | 35.41% | 32.13% | -54.17% | -1596.36% | -6411.65% | - |
| FCF per Share | -4.36 | -4.99 | -6.89 | -10.28 | -8.16 | -1.60 | -0.02 |
| FCF Conversion (FCF/Net Income) | 1.01x | 0.87x | 1.01x | 0.91x | 0.85x | 0.14x | 0.65x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity depletion risk
According to historical financial data, Vincerx exhibits a persistent disconnect between net losses and operating cash flow, with the OCF/NI ratio fluctuating wildly from 0.62 to 3.22, suggesting that accruals and non-cash adjustments significantly distort the underlying reality of the company's cash-based operational depletion.
The volatility in the OCF/NI ratio indicates that net income is a poor proxy for the actual cash requirements of the business. Investors should monitor these fluctuations as they suggest that working capital swings and non-cash expenses are masking the true, consistent rate at which the company consumes its limited capital.
As reported in quarterly filings, Vincerx has maintained a consistently negative free cash flow trajectory, with quarterly outflows reaching as high as $13.8 million, underscoring the company's total reliance on external financing to fund its ongoing research and development activities in the absence of product revenue.
The absence of positive free cash flow is a structural feature of the current clinical-stage model rather than a temporary operational setback. This trajectory suggests that the company remains entirely dependent on capital market access, which may become increasingly difficult to secure given the current cash position.
Based on reported figures, Vincerx's working capital movements have been highly erratic, with quarterly changes ranging from a $3.8 million outflow to a $1.7 million inflow, reflecting the unpredictable nature of managing clinical trial expenses and vendor payables in a pre-revenue, cash-constrained biotechnology environment.
These swings in working capital suggest that management is likely managing cash outflows by timing payments to clinical research organizations and other vendors. Such practices may indicate a reactive approach to liquidity management that could potentially disrupt clinical trial timelines if vendor relationships are strained by payment delays.
As disclosed in recent financial statements, Vincerx has utilized stock-based compensation as a recurring mechanism to preserve cash, with quarterly grants reaching as high as $1.4 million, which effectively shifts the burden of operational costs from current cash reserves to future shareholder dilution.
While this strategy provides a temporary buffer for the company's dwindling cash balance, it warrants further investigation into the long-term impact on equity value. The reliance on equity-based incentives suggests that the company may be struggling to retain essential scientific talent without depleting its remaining liquid assets.
Quick answers to the most common questions about buying VINC stock.
Vincerx Pharma, Inc. (VINC) generated $-26.1M in net cash from operating activities in 2024. This reflects the cash generated directly from core business operations.
Vincerx Pharma, Inc. (VINC) reported negative free cash flow of $26.1M in 2024, indicating capital requirements exceeded cash from operations.
Vincerx Pharma, Inc. (VINC) spent $0.0M on capital expenditures in 2024. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.